Viking Therapeutics/$VKTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Primary listing
Employees
51
Headquarters
Website
VKTX Metrics
BasicAdvanced
$4.2B
-
-$2.12
0.63
-
Price and volume
Market cap
$4.2B
Beta
0.63
52-week high
$65.77
52-week low
$18.92
Average daily volume
4.8M
Financial strength
Current ratio
28.339
Quick ratio
27.413
Long term debt to equity
0.045
Total debt to equity
0.106
Interest coverage (TTM)
-3,435.53%
Profitability
Management effectiveness
Return on assets (TTM)
-20.48%
Return on equity (TTM)
-29.23%
Valuation
Price to book
5.88
Price to tangible book (TTM)
5.88
Price to free cash flow (TTM)
-18.588
Free cash flow yield (TTM)
-5.38%
Free cash flow per share (TTM)
-2.005
Growth
Earnings per share change (TTM)
126.98%
3-year earnings per share growth (CAGR)
38.45%
10-year earnings per share growth (CAGR)
-2.34%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Bulls say / Bears say
Viking has started two Phase 3 VANQUISH studies of subcutaneous VK2735 in obese and type 2 diabetic patients, a major step toward approval, with targets of 4,500 and 1,100 participants that could help streamline the process.
The company ended Q2 2025 with $808 million in cash, providing enough resources to fund the ongoing Phase 3 trials and reducing the likelihood of near-term share dilution.
Viking’s Phase 2 VENTURE-Oral study of VK2735 achieved rapid enrollment completion, showing strong interest from patients and investigators, and setting up top-line results for the second half of 2025.
VK2735’s mid-stage oral trial had a 20% dropout rate due to gastrointestinal side effects, compared to 13% on placebo. This triggered a nearly 35% drop in premarket trading and raises concerns about tolerability ahead of Phase 3.
The FDA’s acceptance of Novo Nordisk’s new drug application (NDA) for oral Wegovy means the first oral GLP-1 therapy could reach the market as soon as Q4 2025, posing strong competition that might restrict VK2735’s market share.
Viking reported a GAAP net loss of $65.6 million in Q2 2025. Research and development expenses rose to $60.2 million with no product revenue, highlighting significant cash burn before commercialization.
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $4.2B as of November 07, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of November 07, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.